Treatment of chronic obstructive pulmonary disease
(COPD) has always been a challenge to the physician.
According to a publication, [Published online
ahead of print March 3, 2016]. Chest.
doi:10.1016/j.chest.2016.02.646, “A systematic review with
meta-analysis of dual bronchodilation with LAMA/LABA for the
treatment of stable chronic obstructive pulmonary disease” by
Calzetta L, Rogliani P, Matera MG, Cazzola M., dual bronchodilation
with Long-acting Muscarinic Antagonists/Long-acting Beta Agonists
(LAMA/LABA) for the treatment of stable chronic obstructive pulmonary
disease (COPD) is more effective than a LAMA or a LABA alone
Dual bronchodilation with Long-acting Muscarinic
Antagonists/Long-acting Beta Agonists (LAMA/LABA) for the treatment
of stable chronic obstructive pulmonary disease (COPD) is more
effective than a LAMA or a LABA alone, regardless of the drugs used.
 |
| Enlarged view of lung tissue showing the difference between healthy lung and COPD (Photo credit: Wikipedia) |
• All LAMA/LABA combinations were always more
effective than the LAMA or LABA alone in terms of improvement in
trough FEV1.
• There was a gradient of effectiveness among
the currently available LAMA/LABA fixed-dose combinations, although
there was not a significant difference among them.
• LAMA/LABA combinations also improved both
quality of life scores, and did not increase the cardiovascular risk
when compared with monocomponents.
There are currently 3 FDA approved LABA/LAMA
combination inhalers:
• Umeclidinium bromide and vilanterol
(Anoro-GSK).
• Glycopyrronium bromide and indacaterol
(Ultibro-Novartis).
...
Click here to Subscribe news feed from "Clinicianonnet; so that you do not miss out anything that can be valuable to you !!
...
Posts
